Oxcarbazepine · Regulatory label update

FDA supplemental approval: Oxcarbazepine (Labeling)

U.S. Food and Drug Administration · May 15, 2026

Insufficient Information Why this matters to you Expert discussion

The material analysed did not support any firm read.

AI Summary

This is a regulatory approval action by the FDA for a supplemental labeling change to oxcarbazepine tablets (150 mg, 300 mg, 600 mg oral formulations) submitted by Rubicon Research. The record documents administrative approval but does not contain clinical trial results, efficacy data, or comparative safety evidence.

What was studied

Regulatory label update.

Key findings

Safety

This is a regulatory approval record, not a clinical trial; no efficacy, safety, or comparative outcome data are reported. This record does not support clinical decision-making regarding oxcarbazepine efficacy or safety relative to alternatives.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for oxcarbazepine labeling update; does not contain clinical trial data or efficacy evidence.

Reported figures

Quoted from the source exactly as published.

Approval status date2026-05-15

Submission classLabeling

Product strengths approved150 mg, 300 mg, 600 mg tablets

Caveats

This is a regulatory approval record, not a clinical trial; no efficacy, safety, or comparative outcome data are reported.
The specific labeling changes made are not detailed in this source.
No clinical study design, sample size, or statistical analysis is present.
This record does not support clinical decision-making regarding oxcarbazepine efficacy or safety relative to alternatives.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no clinical study design present.

Directness

insufficient

Labeling supplement; does not report clinical outcomes or comparative data.

Consistency

insufficient

Single regulatory submission; no comparison group or consistency assessment.

Risk of bias

insufficient

Regulatory approval document; bias assessment not applicable.

Sample adequacy

insufficient

No clinical trial sample; regulatory labeling action only.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA207717. This is a regulatory action record, not a clinical study. Brand name: OXCARBAZEPINE. Active ingredient: OXCARBAZEPINE. Sponsor: RUBICON RESEARCH. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-05-15. Products: OXCARBAZEPINE, TABLET, ORAL, OXCARBAZEPINE 300MG; OXCARBAZEPINE, TABLET, ORAL, OXCARBAZEPINE 600MG; OXCARBAZEPINE, TABLET, ORAL, OXCARBAZEPINE 150MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Rubicon ResearchOxcarbazepine